Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
Earlier this year, Longboard reported topline data from the PACIFIC Phase 1b/2a trial evaluating bexicaserin in participants with DEEs.Truist Securities initiated coverage on Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), citing it as a CNS-focused biotech with high-value epilepsy assets.
Truist Securities開始對Longboard Pharmicals, Inc.（納斯達克股票代碼：LBPH）進行報道，稱其是一家專注於CNS的生物技術公司，擁有高價值的癲癇資產。
The company plans to advance its lead drug bexicaserin (LP352), into the Phase 3 program later this year.
該公司計劃在今年晚些時候將其主要藥物貝西卡色林（LP352）推進到第三階段計劃。
The FDA has granted Breakthrough Therapy designation for bexicaserin for seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older.
美國食品藥品管理局已授予貝西卡色林突破性療法稱號，用於治療兩歲及以上患者的發育和癲癇性腦病（DEE）相關的癲癇發作。
Earlier this year, Longboard reported topline data from the PACIFIC Phase 1b/2a trial evaluating bexicaserin in participants with DEEs.
今年早些時候，Longboard報告了PACIFIC1b/2a期試驗的頭條數據，該試驗評估了DEE參與者的bexicaserin。
Recently, the company revealed interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 with DEEs.
最近，該公司公佈了正在進行的爲期52周的PACIFIC研究的開放標籤延期的中期結果，該研究評估了12-65歲使用DEE的參與者的貝西卡色林（LP352）。
Bexicaserin achieved an overall median seizure reduction of 57.7% in countable motor seizures over an approximate 9-month treatment period.
在大約9個月的治療期內，Bexicaserin實現了可數運動性驚厥的總體發作中位數減少57.7％。
Longboard is also evaluating LP659, which is in development for the potential treatment of rare neuroinflammatory conditions.
Longboard 還在評估 LP659，該產品正在開發中，可能用於治療罕見的神經炎症性疾病。
Truist writes bexicaserin is competitive to current market leader UCB SA (OTC:UCBJY) (OTC:UCBJF) Fintepla (fenfluramine) in epilepsy.
Truist寫道，在癲癇方面，貝西卡色林與現任市場領導者uCb SA（場外交易代碼：UCBJY）（場外交易代碼：UCBJF）Fintepla（芬氟拉明）相比具有競爭力。
The analyst initiates with a Buy rating and a price target of $60.
分析師最初的評級爲買入，目標股價爲60美元。
Fintepla is on track for approximately $1 billion in estimated sales by 2027 per UCB Pharma.
到2027年，Fintepla預計每家uCB Pharma的銷售額約爲10億美元。
The analyst notes that, unlike fenfluramine, bexicaserin does not bind to the 5HT2B receptor, which is linked to the heart-related side effects seen with Fintepla.
分析師指出，與芬氟拉明不同，貝西卡色林不與5HT20受體結合，這與Fintepla的心臟相關副作用有關。
"Based on bexicaserin's superior safety and comparable efficacy to Fintepla, we think bexicaserin could not only displace Fintepla but also further expand the market, which remains under-penetrated at around 5%," Truist analyst writes.
Truist分析師寫道：「基於bexicaserin卓越的安全性和與Fintepla相當的療效，我們認爲bexicaserin不僅可以取代Fintepla，還可以進一步擴大市場，市場滲透率仍不足，約爲5％。」
Price Action: LBPH stock is up 0.20% at $34.58 at last check Tuesday.
價格走勢：週二最後一次檢查時，LBPH股價上漲0.20％，至34.58美元。
- SiriusXM's Next Chapter: Charts Independent Path With Buybacks & Streamlined Capital Structure
- SiriusXM 的下一章：通過回購和簡化的資本結構開闢獨立路徑
譯文內容由第三人軟體翻譯。
